Health Economics›Dermatofibrosarcoma protuberans›All lines of therapy

All lines of therapy

Dermatofibrosarcoma protuberans · 1 regimen

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Imatinib monotherapy Variant #17	—	R 27 014	30d	~20.0 mo	~53.0 mo	~21	~R 567 284 PFS proxy · indirect	8

1 of 1 regimen shown